Cover Image
市場調查報告書

靜脈注射鐵劑的全球市場

Intravenous (IV) Iron Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 134325
出版日期 內容資訊 英文 135 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
靜脈注射鐵劑的全球市場 Intravenous (IV) Iron Drugs
出版日期: 2015年01月01日 內容資訊: 英文 135 Pages
簡介

本報告提供全球靜脈注射鐵劑市場相關調查,提供產業趨勢,各地區趨勢,市場預測,加入此市場的主要企業簡介等彙整資料,為您概述為以下內容。

第1章 簡介,方法,產品定義

第2章 摘要整理

  • 預測
    • 靜脈注射鐵劑市場:概要
    • 美國·歐洲支配靜脈注射鐵劑市場
    • 亞太地區:急速成長市場
    • 不受不景氣影響的市場成長
    • 醫療產業的樂觀預測所顯示出的展望
  • 產業概要及趨勢
    • IDA和治療:概要
    • 透析診所:靜脈注射鐵劑補充品的主要市場
    • 靜脈注射鐵劑:概要
    • 缺鐵所下處方的主要靜脈注射鐵劑,其他
  • 法律規章概要
    • 一次性給付趨勢
    • 歐美的法律規章概要
    • FDA認證的靜脈注射鐵劑之核準適應比較和安全性警告
    • 比利時,德國,荷蘭,英國,法國,美國,加拿大的安大略透析服務的給付配套之靜脈注射鐵劑和ESA
  • 靜脈注射鐵劑概要
    • 鐵:不可缺少的因子
    • 缺鐵性貧血
    • 靜脈注射治療
    • 慢性疾病,高齡女性患者:高風險人口
    • 缺鐵性貧血的治療
    • 慢性腎臟病(CKD)上鐵的必要性
    • CKD的缺鐵分類
    • CKD患者的缺鐵治療
    • CKD鐵劑補充品的副作用
    • 鐵復原法
    • 口服鐵劑治療
    • 靜脈注射鐵劑輸液治療
    • 鐵劑注射的高價
    • 實驗數量的必要條件
    • 鐵劑注射的副作用
    • 鐵劑治療:警告
    • 鐵劑注射的期間
    • 鐵劑過量攝取
    • 鐵劑不平衡治療
  • 產品引進/認證
    • FDA核凖通過IDA治療用Injectafer
    • 武田藥品工業在歐洲推出Rienso
    • Pharmacosmos推出靜脈注射鐵劑Monofer
  • 近幾年的產業活動
  • 主要企業
    • Actavis, Inc.
    • AMAG Pharmaceuticals, Inc.
    • Fresenius Medical Care AG & Co. KGaA
    • Galenica Ltd.
    • Vifor Pharma Ltd.
    • Luitpold Pharmaceuticals, Inc.
    • American Regent, Inc.
    • Pharmacosmos A/S
    • Sanofi US
    • 武田藥品工業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他
  • 亞太地區各國
    • 中國
    • 印度
    • 其他
  • 南美
  • 其他各國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6464

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -

Actavis, Inc.
AMAG Pharmaceuticals, Inc.
Fresenius Medical Care AG & Co. KGaA
Galenica Ltd.
Luitpold Pharmaceuticals, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK

  • IV Iron Drugs Market - A Quick Primer
  • US and Europe Dominate IV Iron Market
  • Asia-Pacific - The Fastest Growing Market
  • Recession Fails to Affect Market Growth
  • Positive Outlook for the Healthcare Industry Signals Prospects
    • Table 1: Healthcare Spending as a Percentage of GDP in Select Countries (includes corresponding Graph/Chart)

2. INDUSTRY OVERVIEW & TRENDS

  • IDA and Treatment - An Overview
  • Dialysis Clinics - Major Market for IV Iron Supplements
    • Table 2: World Distribution of Dialysis Patients by Country (2013): Number of Patients in Thousands for Brazil, China, Japan, Mexico, US and Others (includes corresponding Graph/Chart)
    • Table 3: World Dialysis Prevalence by Country (2013): Prevalence in Patients per Million Population for Brazil, China, Japan, Mexico, US and Others (includes corresponding Graph/Chart)
    • Table 4: Global Iron Deficiency Anemia Prevalence by Risk Groups - Preschool Children, School-age Children, Pregnant Women, Non-Pregnant Women, Men and Elderly Analyzed by Prevalence Percentage (includes corresponding Graph/Chart)
    • Table 5: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Number of Patients with ID and IDA in CKD (with dialysis), Non-Dialysis-CKD, Congestive Heart Failure, Chemotherapy Induced Anemia, Irritable Bowel Disease, Patient Blood Management (Surgery), Heavy Uterine Bleeding and Postpartum (OB-GYN) (includes corresponding Graph/Chart)
  • IV Iron Drugs - An Overview
  • Select IV Iron Drugs Prescribed for Iron Deficiency
    • Table 6: Global Sales of Select IV Iron Drugs in US$ Million: 2013 (includes corresponding Graph/Chart)
  • Galenica - The Global Leader in IV Iron
    • Venofer® - Galenica's Wonder Drug
      • Venofer Continues to Lose Ground
    • Ferinject/Injectafer - A Promising Revenue Spinner for Galenica
  • Feraheme Surges Ahead; Manufacturer Eyes Expansion of Indications
  • The Vulnerable Ageing Population Supports Demand
    • Table 7: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013E (includes corresponding Graph/Chart)
  • Changing Preferences Favor IV Iron Drugs
  • Comparison of Ferrous Salts with IV Iron Therapy
  • Chronic Kidney Disease - The Predominant Growth Factor
  • Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
  • Anemia in Heart Failure - A Market with Huge Potential
  • Chemotherapy Induced Anemia to Promote IV Iron Supplements
    • Table 8: Global Cancer Incidence by Region (2012): Number of New Cancer Cases for Asia-Pacific, Europe, North and South America, and Africa (includes corresponding Graph/Chart)
  • Correction of IDA in Pregnancy Signals Opportunities
  • Women's Health - Key Growth Opportunity
  • Perioperative and Postoperative Anemia - A Niche Market Beckons
  • Adverse Reactions of IV Iron Preparations Raise Concerns
  • Peginesatide - A Possible Threat to IV Iron
  • Dosing Limitations Plague IV Iron Market
  • Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW

  • Increasing Trend towards Bundled Reimbursements
  • A Glimpse of Regulations in the US and Europe
  • Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
  • Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS

  • Iron - A Vital Element
  • Iron-Deficiency Anemia
  • Intravenous Therapy
  • Patients of Chronic Illnesses, the Elderly and Women - The High Risk Population
  • Treatment for Iron Deficiency Anemia
  • Iron Requirement in Chronic Kidney Disease
  • Classification of Iron Deficiency in CKD
  • Treating Iron Deficiency in CKD Patients
  • Side Effects of Iron Supplementation in CKD
  • Methods of Restoring Iron
  • Oral Iron Therapy
  • IV Iron-Infusion Therapy
    • Intravenous (IV) Iron
    • Conditions for Receiving Iron Injections
    • Injection Procedure
    • Categories of Iron Injections
    • Suitability of IV Iron Preparation
    • Suitability of Regimen
    • Management of Iron Doses
  • Effectiveness of Iron Injection
  • Requirement of Test Dose
  • Adverse Effects of Iron Injections
  • Iron Therapy: Caution
  • Duration of Iron Infusion
  • Iron Overdose
  • Iron-Out-of-Balance Therapies
    • Blood Donation
    • Therapeutic Phlebotomy
    • Red Cell Apheresis
    • Iron Chelation Therapy
      • Iron-Chelating Drugs
      • Desferrioxamine or Desferal
      • Deferiprone or Ferriprox
      • Conditions for Undergoing Iron Chelation Therapy
      • Kinds of Chelation Therapy
      • Side Effects Caused by IV Iron Chelation

5. PRODUCT LAUNCHES/APPROVALS

  • FDA approves Injectafer® for the Treatment of IDA
  • Takeda Pharmaceutical Company Introduces Rienso® in Europe
  • Pharmacosmos Launches Monofer® Intravenous Iron Drug

6. RECENT INDUSTRY ACTIVITY

  • American Regent Steps Up Injectafer® Promotions
  • AMAG Files for Rienso Label Expansion in Europe
  • AMAG Receives FDA Complete Response Letter for Feraheme®
  • Vifor Pharma and Zeria Pharmaceutical Co., Ltd. Sign Exclusive Licensing Agreement for Ferinject® in Japan
  • Watson Pharmaceuticals Changes Name to Actavis
  • Luitpold Pharmaceuticals Obtains FDA Acceptance for Review of Injectafer® NDA
  • AMAG Pharmaceuticals Receives FDA Acceptance for Feraheme® sNDA Review
  • Takeda Issues Rienso Recall in Switzerland
  • EC Approves Takeda's Rienso® to Treat Anemia
  • BioLink Life Sciences to Commence Phase I Trial of FCP

7. FOCUS ON SELECT PLAYERS

  • Actavis, Inc. (US)
  • AMAG Pharmaceuticals, Inc. (US)
  • Fresenius Medical Care AG & Co. KGaA (Germany)
  • Galenica Ltd. (Switzerland)
  • Vifor Pharma Ltd. (Switzerland)
  • Luitpold Pharmaceuticals, Inc. (US)
  • American Regent, Inc. (US)
  • Pharmacosmos A/S (Denmark)
  • Sanofi US (US)
  • Takeda Pharmaceutical Company Limited (Japan)

8. GLOBAL MARKET PERSPECTIVE

    • Table 9: World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 10: World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 11: World 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
    • CKD Fuels the US Market for IV Iron
    • Addressing Broader IDA Indicates Opportunities
    • CMS Reimbursement Shifts to Bundled Payment for Dialysis
      • Comparison of the Old (Fixed Payment) and Bundled Payment Reimbursement Models
    • The Anticipated Effect of Bundling Reimbursement on Clinical Practice
      • ESRD QIP Related Measures for the Years 2012, 2013 and 2014
    • Concerns over Allergic Reactions Prompts FDA to Issue Warning
      • Potential Short-Term and Long-Term Safety Concerns of IV Iron Preparations
    • Competitive Scenario
    • Table 12: Leading IV Iron Drugs in the US Market (2013): Percentage Breakdown of Value Sales for Feraheme, Ferrlecit, Venofer and Others (includes corresponding Graph/Chart)
    • Table 13: Leading Drugs in the US Non-Dialysis IV Iron Market (2011 & 2013): Percentage Breakdown of Volume Sales for Feraheme, Ferrlecit + Generic Ferric Gluconate, Venofer and Others (includes corresponding Graph/Chart)
    • Table 14: Iron Deficiency Prevalence by Disease: Analyzed by Percentage Share of Patients with ID and IDA for Select Diseases (includes corresponding Graph/Chart)
    • Table 15: Preferred Therapy for New ESRD Patients in the US: Percentage Breakdown by Number of Patients Opting for Hemodialysis, Transplant and Peritoneal Dialysis (includes corresponding Graph/Chart)
    • Does Dose Limitation Affect Venofer's Sales?
    • Product Approval
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 16: US Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 17: US Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 18: Canadian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 19: Canadian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Market Overview
    • Bundled Payment Policy Encourages IV Iron Use
    • Strategic Corporate Development
    • Takeda Pharmaceutical Company Limited - A Key Player
  • B. Market Analytics
    • Table 20: Japanese Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 21: Japanese Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Research Thrusts IV Iron Therapies into Limelight
      • List of Available IV Iron Drugs in Europe
    • An Overview of the Competitive Landscape
    • Table 22: Leading IV Iron Drugs in Europe (2013): Percentage Share Breakdown of Value Sales for Cosmofer, Ferinject, Ferrlecit/Gluconate, Generics, Iron Sucrose Similars (ISS), Venofer, and Others (includes corresponding Graph/Chart)
    • EMA Issues New Precautionary Guidelines for IV Iron Supplements
    • Product Launch
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 23: European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 24: European Historic Review for Intravenous (IV) Iron Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 25: European 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • Market Analysis
    • Table 26: French Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 27: French Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Fresenius Medical Care Ag & Co. Kgaa - A Key Player
  • B. Market Analytics
    • Table 28: German Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 29: German Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 30: Italian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 31: Italian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • Market Analysis
    • Table 32: UK Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 33: UK Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 34: Spanish Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 35: Spanish Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 36: Russian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 37: Russian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • IV Iron Market in Switzerland
    • Table 38: Swiss IV Iron Market by Therapeutic Area: Percentage Breakdown of Value Sales for Cardiology, Gastroenterology, Geriatry, Gynaecology, Internal Medicine, Nephrology, Oncology, and Others (includes corresponding Graph/Chart)
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 39: Rest of European Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 40: Rest of European Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • Market Analysis
    • Table 41: Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region/Country - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 42: Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region/Country - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 43: Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5a. CHINA

  • Market Analysis
    • Table 44: Chinese Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 45: Chinese Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5b. INDIA

  • Market Analysis
    • Table 46: Indian Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 47: Indian Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • Market Analysis
    • Table 48: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 49: Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 50: Latin American Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 51: Latin American Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 52: Latin American 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • Market Analysis
    • Table 53: Rest of World Recent Past, Current and Future Analysis for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 54: Rest of World Historic Review for Intravenous (IV) Iron Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top